- Home
- OCTO vs GLTO Comparison
OCTO vs GLTO Comparison
Compare OCTO & GLTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OCTO
- GLTO
- Stock Information
- Founded
- OCTO 1966
- GLTO 2011
- Country
- OCTO United States
- GLTO Denmark
- Employees
- OCTO N/A
- GLTO N/A
- Industry
- OCTO
- GLTO Biotechnology: Pharmaceutical Preparations
- Sector
- OCTO
- GLTO Health Care
- Exchange
- OCTO Nasdaq
- GLTO Nasdaq
- Market Cap
- OCTO 4.2M
- GLTO 4.4M
- IPO Year
- OCTO N/A
- GLTO 2020
- Fundamental
- Price
- OCTO $1.18
- GLTO $3.45
- Analyst Decision
- OCTO
- GLTO Buy
- Analyst Count
- OCTO 0
- GLTO 1
- Target Price
- OCTO N/A
- GLTO $10.00
- AVG Volume (30 Days)
- OCTO 13.0K
- GLTO 16.8K
- Earning Date
- OCTO 08-13-2025
- GLTO 08-11-2025
- Dividend Yield
- OCTO N/A
- GLTO N/A
- EPS Growth
- OCTO N/A
- GLTO N/A
- EPS
- OCTO N/A
- GLTO N/A
- Revenue
- OCTO $41,576,562.00
- GLTO N/A
- Revenue This Year
- OCTO N/A
- GLTO N/A
- Revenue Next Year
- OCTO N/A
- GLTO N/A
- P/E Ratio
- OCTO N/A
- GLTO N/A
- Revenue Growth
- OCTO N/A
- GLTO N/A
- 52 Week Low
- OCTO $0.98
- GLTO $2.01
- 52 Week High
- OCTO $4.86
- GLTO $16.07
- Technical
- Relative Strength Index (RSI)
- OCTO 44.86
- GLTO 64.94
- Support Level
- OCTO $1.17
- GLTO $3.10
- Resistance Level
- OCTO $1.25
- GLTO $3.65
- Average True Range (ATR)
- OCTO 0.07
- GLTO 0.23
- MACD
- OCTO 0.00
- GLTO 0.00
- Stochastic Oscillator
- OCTO 61.90
- GLTO 81.10
About OCTO Eightco Holdings Inc.
Eightco Holdings Inc operates in Forever 8 Inventory Cash Flow Solution. The company is a dynamic technology-focused company committed to driving growth and innovation through strategic acquisitions and management. Forever 8 focuses on purchasing inventory for e-commerce retailers and is part of its Inventory Solution Business.
About GLTO Galecto Inc.
Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of cancer and liver diseases. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis.